指南与共识细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

成人COVID-19抗菌治疗推荐:基于证据的指南

Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline.
指南 / 共识 · Clin Microbiol Infect · 2020-10-01

荷兰抗生素政策工作组组织多学科专家委员会,基于文献检索与GRADE方法,为住院成人COVID-19疑似或确诊呼吸道感染患者的抗菌治疗提供推荐。入院时细菌合并感染报告为3.5%,住院期间继发细菌感染可达15%。证据支持限制性使用抗生素,尤其入院时,并建议48小时后培养及尿抗原阴性即停用经验性抗生素。

要点

  • 入院时细菌合并感染约3.5%,住院继发感染可达15%。
  • 证据支持限制性抗生素使用,尤其入院时。
  • 入院经验性抗生素48小时后培养及尿抗原阴性建议停用。

核心结论

  • 现有证据支持从抗菌药物管理角度对COVID-19患者限制性使用抗生素,尤其入院时。
  • 继发细菌性呼吸道感染建议遵循医院获得性肺炎和呼吸机相关性肺炎的抗菌治疗指南。
  • COVID-19疑似细菌性呼吸道感染患者在体征、症状和炎症标志物改善时推荐抗生素疗程为5天。

研究设计与样本

  • 荷兰抗生素政策工作组组成多学科专家委员会制定本指南。
  • 通过文献检索回答四个关键问题,并采用GRADE方法对证据分级并形成推荐。

主要发现

  • 入院时细菌合并感染报告于3.5%的COVID-19患者。
  • 住院期间继发细菌感染发生率可达15%。
  • 回答其他关键临床问题的证据为无或极低质量。

关键数值与推荐

  • 入院时细菌合并感染报告为3.5%。
  • 住院期间继发细菌感染可达15%。
  • 入院经验性抗生素在48小时后代表性培养及尿抗原检测无细菌病原体受累迹象时建议停用。
  • COVID-19疑似细菌性呼吸道感染在体征、症状和炎症标志物改善时推荐抗生素疗程为5天。

临床怎么用

  • 应尽最大努力获取痰和血培养样本以及肺炎球菌尿抗原检测以支持限制性抗生素使用。
  • 入院时开始抗生素的患者,48小时后代表性培养及尿抗原检测无细菌病原体受累迹象时建议停用。
  • 继发细菌性呼吸道感染患者建议遵循医院获得性肺炎和呼吸机相关性肺炎的抗菌治疗指南。

局限性

  • COVID-19中细菌感染的证据基础目前有限。
  • 回答其他关键临床问题的证据为无或极低质量。
  • 需要更大规模的前瞻性研究来确认结论并最终防止COVID-19大流行期间不必要的抗生素使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SCOPE: The Dutch Working Party on Antibiotic Policy constituted a multidisciplinary expert committee to provide evidence-based recommendation for the use of antibacterial therapy in hospitalized adults with a respiratory infection and suspected or proven 2019 Coronavirus disease (COVID-19). METHODS: We performed a literature search to answer four key questions. The committee graded the evidence and developed recommendations by using Grading of Recommendations Assessment, Development, and Evaluation methodology. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: We assessed evidence on the risk of bacterial infections in hospitalized COVID-19 patients, the associated bacterial pathogens, how to diagnose bacterial infections and how to treat bacterial infections. Bacterial co-infection upon admission was reported in 3.5% of COVID-19 patients, while bacterial secondary infections during hospitalization occurred up to 15%. No or very low quality evidence was found to answer the other key clinical questions. Although the evidence base on bacterial infections in COVID-19 is currently limited, available evidence supports restrictive antibiotic use from an antibiotic stewardship perspective, especially upon admission. To support restrictive antibiotic use, maximum efforts should be undertaken to obtain sputum and blood culture samples as well as pneumococcal urinary antigen testing. We suggest to stop antibiotics in patients who started antibiotic treatment upon admission when representative cultures as well as urinary antigen tests show no signs of involvement of bacterial pathogens after 48 hours. For patients with secondary bacterial respiratory infection we recommend to follow other guideline recommendations on antibacterial treatment for patients with hospital-acquired and ventilator-associated pneumonia. An antibiotic treatment duration of five days in patients with COVID-19 and suspected bacterial respiratory infection is recommended upon improvement of signs, symptoms and inflammatory markers. Larger, prospective studies about the epidemiology of bacterial infections in COVID-19 are urgently needed to confirm our conclusions and ultimately prevent unnecessary antibiotic use during the COVID-19 pandemic.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. Clin Microbiol Infect. 2020. PMID: 33010444. doi:10.1016/j.cmi.2020.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。